TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17570206

Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy (clarithromycin 750 mg/day, rifabutin 450 mg/day, clofazimine 50 mg/day)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Combination antibiotic therapy
Number of subjects: 213
Study: 15389195

Group type: EXPERIMENTAL
Intervention: Preoperative tumor curettage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 11222109

Group type: EXPERIMENTAL
Intervention: Ethidium-binding assay of DNA damage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiobarbituric acid test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Catalytic iron index
Number of subjects: 20
Study: 9356530

Group type: EXPERIMENTAL
Intervention: Beta-carotene alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Canthaxanthin alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined dose of beta-carotene and canthaxanthin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Canthaxanthin
Number of subjects: 9
Study: 7524457

Group type: EXPERIMENTAL
Intervention: Topical aprotinin (50 mL; 70 mg)
Number of subjects: 100
Study: 3036335

Group type: EXPERIMENTAL
Intervention: New drugs and drug combinations for recurrent Wilms' tumor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for localized embryonal rhabdomyosarcoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy for tumors of the prostate, bladder neck, or trigone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-containing combination chemotherapy regimens for advanced yolk sac tumor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New drug combinations in locally advanced tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoposide-containing combination chemotherapy regimens
Number of subjects: 0
Study: 29358433

Group type: EXPERIMENTAL
Intervention: Standard treatment + prescribed fluid intake
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard treatment + usual fluid intake
Number of subjects: 180
Study: 26708858

Group type: EXPERIMENTAL
Intervention: Truncal ligation of ITA
Number of subjects: 184

Group type: COMPARATOR
Intervention: Terminal branches ligation of ITA
Number of subjects: 184
Study: 25906703

Group type: EXPERIMENTAL
Intervention: Electronic previsit questionnaire (PVQ) with youth violence (YV) questions
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (PVQ without YV questions)
Number of subjects: 183
Study: 22958170

Group type: EXPERIMENTAL
Intervention: Chronic alcohol abuse in PS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: No history of alcohol abuse in PS patients
Number of subjects: 0
Study: 20569152

Group type: EXPERIMENTAL
Intervention: Preference arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized arm
Number of subjects: 0
Study: 18465724

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 5854

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5854
Study: 16495196

Group type: EXPERIMENTAL
Intervention: MDNP model (multidisciplinary doctor-nurse practitioner)
Number of subjects: 1207
Study: 12434259

Group type: EXPERIMENTAL
Intervention: 200 mg/70 kg oral caffeine t.i.d. (caffeine maintenance)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo t.i.d. (control)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous nicotine (1.0 and 2.0 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (200 and 400 mg/70 kg)
Number of subjects: 9
Study: 10845019

Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluorescein angiography
Number of subjects: 10
Study: 9085325

Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acyclovir
Number of subjects: 0
Study: 8473463

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 23
Study: 3513529

Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg/day, adjustable to max 3 mg/day)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 249
Study: 30388105

Group type: EXPERIMENTAL
Intervention: Dengue seroprevalence levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dengue force of infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population density
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: City administrative status
Number of subjects: 0
Study: 28298187

Group type: EXPERIMENTAL
Intervention: internet-delivered transdiagnostic cognitive behavioural therapy (iCBT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 90
Study: 26181090

Group type: EXPERIMENTAL
Intervention: Family planning services (counseling, prescription or procedure related to birth control)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Tiers I‐II contraceptive methods (sterilization and hormonal)
Number of subjects: 295
Study: 23246170

Group type: EXPERIMENTAL
Intervention: Aquatic biodance
Number of subjects: 59

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 59
Study: 21215558

Group type: COMPARATOR
Intervention: Upper-limb aerobic exercise training (ULG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Lower-limb aerobic exercise training (LLG)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Non-exercise control group
Number of subjects: 104
Study: 18318607

Group type: EXPERIMENTAL
Intervention: Unlocalized amplitude information with phase randomization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Localized amplitude information (control)
Number of subjects: 0
Study: 16413605

Group type: EXPERIMENTAL
Intervention: Classroom only intervention
Number of subjects: 1578

Group type: EXPERIMENTAL
Intervention: Classroom plus semester-long school-as-community component
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 1578
Study: 12804986

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 mug/g ointment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Calcipotriol 50 mug/g ointment
Number of subjects: 125
Study: 10989245

Group type: EXPERIMENTAL
Intervention: Tibolone therapy (group T)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Continuous conjugated estrogen (CE) 0.625 mg plus medroxyprogesterone acetate (MPA) 2.5 mg (group E)
Number of subjects: 50
Study: 8865212

Group type: EXPERIMENTAL
Intervention: Individually programmed AV delay (optimal AV delay)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Individually programmed AV delay (most unfavorable AV delay)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Functional status questionnaire
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Total judgment score for optimal AV delay
Number of subjects: 13

Group type: COMPARATOR
Intervention: Total judgment score for most unfavorable AV delay
Number of subjects: 13
Study: 1475418

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 40
Study: 6533776

Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis with 8-h dosage interval (500 mg intravenous infusion)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis with 12-h dosage interval (500 mg intravenous infusion)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tinidazole prophylaxis (500 mg intravenous infusion)
Number of subjects: 48
Study: 31394276

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29941020

Group type: EXPERIMENTAL
Intervention: Tailored intervention comprising a distance professional training program on shared decision-making and five shared decision-making tools.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Immediate exposure to the intervention
Number of subjects: 180

Group type: COMPARATOR
Intervention: Delayed exposure to the intervention
Number of subjects: 180
Study: 27565938

Group type: EXPERIMENTAL
Intervention: ramucirumab plus docetaxel
Number of subjects: 160

Group type: COMPARATOR
Intervention: placebo plus docetaxel
Number of subjects: 160
Study: 25587312

Group type: EXPERIMENTAL
Intervention: 2 g magnesium sulfate in normal saline infused in 20 minutes on days one to three (case group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard medications and placebo (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 g magnesium sulfate in normal saline (case group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (case group)
Number of subjects: 30
Study: 22968127

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy combined with a standardized physical therapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized physical therapy program alone
Number of subjects: 0
Study: 21210927

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 16) undergoing psychological stress during a college academic final test
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n = 17) not undergoing the test
Number of subjects: 33
Study: 17030560

Group type: EXPERIMENTAL
Intervention: 3 h of cycle ergometer exercise at 60% of maximum oxygen uptake
Number of subjects: 15

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study: 15729066

Group type: EXPERIMENTAL
Intervention: Virtual Endoscopic Surgery Trainer (VEST)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional Video Trainer (CVT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control task on Day 5
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 32
Study: 12170856

Group type: EXPERIMENTAL
Intervention: Two-implant overdenture on ball attachments
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 60
Study: 11158794

Group type: COMPARATOR
Intervention: No treatment (observed without therapy)
Number of subjects: 160
Study: 9043967

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (food-based diets)
Number of subjects: 110
Study: 8183101

Group type: EXPERIMENTAL
Intervention: Glucose polymer-electrolyte beverage (GP; N = 24)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tap water (TW; N = 24)
Number of subjects: 48
Study: 3654426

Group type: EXPERIMENTAL
Intervention: Ice packs applied to the skin of the face, chest, thigh, and upper arm; random sequence; specific conductance measured
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of frigid air
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Breathing cold air at rest
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Elevating ventilation in a cold environment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Warm packs applied to the same areas
Number of subjects: 23
Study: 29725986

Group type: EXPERIMENTAL
Intervention: Active analgesic treatment (paracetamol or buprenorphine transdermal system)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 162
Study: 26103778

Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis with nifedipine
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 236
Study: 25802960

Group type: EXPERIMENTAL
Intervention: High Interval Training (HIT) at 85%-95% of heart rate reserve, 3 days a week for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) at 70%-85% of heart rate reserve, 3 days a week for 6 weeks
Number of subjects: 28
Study: 23921272

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 94

Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 94
Study: 20626273

Group type: EXPERIMENTAL
Intervention: LESS‐SN
Number of subjects: 27

Group type: COMPARATOR
Intervention: CTL‐SN
Number of subjects: 27
Study: 19033417

Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IAPP replacement using pramlintide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Meal-derived glucose appearance in plasma
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Splanchnic glucose sequestration
Number of subjects: 25
Study: 16816307

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (n=21)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (n=23)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting-list control (n=18)
Number of subjects: 62
Study: 12784590

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg per kg body weight, administered over 3 days)
Number of subjects: 268
Study: 10791849

Group type: EXPERIMENTAL
Intervention: Chemotherapy (+) in TS-(+) group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Chemotherapy (-) in TS-(+) group
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Chemotherapy (+) in TS-(‐) group
Number of subjects: 148

Group type: COMPARATOR
Intervention: Chemotherapy (-) in TS-(‐) group
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: TS-(‐) group
Number of subjects: 148

Group type: COMPARATOR
Intervention: TS-(+) group
Number of subjects: 148
Study: 8651843

Group type: EXPERIMENTAL
Intervention: Informational intervention simulating an informed consent presentation (n = 103)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Single sentence about the PSA (control group, n = 102)
Number of subjects: 205
Study: 1495743

Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray (300 MRC units)
Number of subjects: 0
Study: 30856378

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CBT and fluoxetine (COMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT) vs. Fluoxetine (FLX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (FLX) vs. Combination of CBT and fluoxetine (COMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT) vs. Combination of CBT and fluoxetine (COMB)
Number of subjects: 0
Study: 29408163

Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Action observation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 26909789

Group type: EXPERIMENTAL
Intervention: Experimental arm (handgrip exercise with blood flow restriction)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control arm (handgrip exercise without blood flow restriction)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 9
Study: 24515550

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention involving medication reconciliation, patient education, and improved communication of the discharge medication plan.
Number of subjects: 592

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 592
Study: 22639800

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Plastic curets + cotton pellets + sterile saline (CPS)
Number of subjects: 24
Study: 19654548

Group type: EXPERIMENTAL
Intervention: BMC therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 17426306

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study: 16361188

Group type: EXPERIMENTAL
Intervention: Early surgery (6-24 months)
Number of subjects: 532

Group type: COMPARATOR
Intervention: Late surgery (32-60 months)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 532
Study: 12572637

Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.836% sodium monofluorophosphate (1100 ppm F) in a dicalcium phosphate dihydrate base plus 10% xylitol
Number of subjects: 2539

Group type: COMPARATOR
Intervention: Positive control dentifrice containing 0.836% sodium monofluorophosphate (1100 ppm F) in a dicalcium phosphate dihydrate base
Number of subjects: 2539
Study: 9854660

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 50 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 150 mg/kg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 150
Study: 8568017

Group type: EXPERIMENTAL
Intervention: Atorvastatin with food (medium-fat breakfast)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atorvastatin without food (fasting)
Number of subjects: 16
Study: 2403428

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 38178

Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (sulfasalazine, prednisone, or placebo)
Number of subjects: 113
Study: 30676887

Group type: EXPERIMENTAL
Intervention: Hinting Task (HT) performance
Number of subjects: 132
Study: 27796131

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 51

Group type: COMPARATOR
Intervention: ZDV/sdNVP
Number of subjects: 51
Study: 26466809

Group type: COMPARATOR
Intervention: Standard intervention A: continuance of oral intake and regular mouth care
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration
Number of subjects: 12
Study: 23410777

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: 1 transfusion cycle (fresh-frozen plasma/platelets)
Number of subjects: 61

Group type: COMPARATOR
Intervention: 2 transfusion cycles (fresh-frozen plasma and platelets)
Number of subjects: 61
Study: 21385928

Group type: EXPERIMENTAL
Intervention: sulindac (300 mg daily)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: etodolac (400 mg daily)
Number of subjects: 189

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 189
Study: 18977478

Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg once daily for 2 months
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg once daily for 2 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17847756

Group type: EXPERIMENTAL
Intervention: LUNA alone
Number of subjects: 67

Group type: COMPARATOR
Intervention: LUNA plus PN
Number of subjects: 67
Study: 15018257

Group type: EXPERIMENTAL
Intervention: Simulated patient visits
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-intervention survey of pharmacists
Number of subjects: 60
Study: 11310931

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Taurine admixture
Number of subjects: 15
Study: 9380241

Group type: EXPERIMENTAL
Intervention: Active-type vitamin D3 (VD) administered to Group 2 (19 patients; 10 males and 9 females)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No active-type vitamin D3 (VD) administered to Group 1 (19 patients; 15 males and 4 females)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Class III oxyphilic cell area
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Class I oxyphilic cell area
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All classes of oxyphilic cell area
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HS- and C-PTH levels in the serum
Number of subjects: 38
Study: 7700068

Group type: EXPERIMENTAL
Intervention: Antihypertension therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Event-based trials
Number of subjects: 0
Study: 3606369

Group type: EXPERIMENTAL
Intervention: Workbook-based program for energy conservation behaviors
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard occupational therapy (OT)
Number of subjects: 25
Study: 30564950

Group type: EXPERIMENTAL
Intervention: Incomplete or absent recovery of echocardiographic parameters at 6 months
Number of subjects: 219
Study: 27854064

Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel 10 mg
Number of subjects: 0
Study: 25237132

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Education-only intervention (control)
Number of subjects: 56
Study: 23391676

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 or 120 mg daily
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 551

Group type: COMPARATOR
Intervention: Allopurinol 300 mg daily
Number of subjects: 551
Study: 21184110

Group type: EXPERIMENTAL
Intervention: Robotic suturing
Number of subjects: 117

Group type: COMPARATOR
Intervention: Laparoscopic suturing
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Preference for suturing method
Number of subjects: 117
Study: 19470936

Group type: EXPERIMENTAL
Intervention: MDM2 overexpression
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Ki-67 overexpression
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: P53 overexpression
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Combined overexpression of Ki-67 and MDM2
Number of subjects: 478
Study: 17094002

Group type: EXPERIMENTAL
Intervention: Computer-assisted cervical pedicle screw insertion (Navigation group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional cervical pedicle screw insertion (Conventional group)
Number of subjects: 27
Study: 16422960

Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg or 20 mg
Number of subjects: 1385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1385